SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Cyclacel Pharmaceuticals, Inc.'s Sapacitabine Nearly Doubles Expected Survival of Elderly Patients With MDS After Front-Line Therapy Failure